$VBIV
VBI Vaccines Inc.
PRICE
$2.88 ▲5.109%
Extented Hours
VOLUME
32,886
DAY RANGE
2.7 - 2.91
52 WEEK
2.35 - 40.5
Join Discuss about VBIV with like-minded investors
@Romanpo #StockTraders.NET
lol for sure but the $GOGO trade is from vbiv lesson lol
68 Replies 12 👍 15 🔥
Key Metrics
Market Cap
24.53 M
Beta
1.79
Avg. Volume
67.81 K
Shares Outstanding
8.61 M
Yield
0%
Public Float
0
Next Earnings Date
Next Dividend Date
Company Information
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
HQ: ,
Related News